154 related articles for article (PubMed ID: 12731520)
41. Risks and benefits of gene therapy.
Noguchi P
N Engl J Med; 2003 Jan; 348(3):193-4. PubMed ID: 12529458
[No Abstract] [Full Text] [Related]
42. Gene therapy.
Heslop HE
Cytotherapy; 2007; 9(6):519-20. PubMed ID: 17882715
[No Abstract] [Full Text] [Related]
43. Panel advises resuming genetic studies: U.S. agency halted trials after boy fell ill in French experiment.
Stolberg SG
N Y Times Web; 2002 Oct; ():A30. PubMed ID: 12474841
[No Abstract] [Full Text] [Related]
44. Trials are halted on gene therapy: child in experiment falls ill--new setback for research.
Stolberg SG
N Y Times Web; 2002 Oct; ():A1, A25. PubMed ID: 12474837
[No Abstract] [Full Text] [Related]
45. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
[TBL] [Abstract][Full Text] [Related]
46. [The current status of gene therapy in severe immunodeficiency].
Winckler T
Pharm Unserer Zeit; 2009; 38(3):204-6. PubMed ID: 19396911
[No Abstract] [Full Text] [Related]
47. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.
Bester AC; Schwartz M; Schmidt M; Garrigue A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Ben-Porat N; Von Kalle C; Fischer A; Kerem B
Gene Ther; 2006 Jul; 13(13):1057-9. PubMed ID: 16511518
[TBL] [Abstract][Full Text] [Related]
48. FDA halts 27 gene therapy trials after illness: leukemia-like cases in 2 children in France prompt the action.
Pollack A
N Y Times Web; 2003 Jan; ():A1, A17. PubMed ID: 12647754
[No Abstract] [Full Text] [Related]
49. Lessons learned from gene therapy concerning and the use of integrating vectors and the possible risk of insertional oncogenesis.
Cichutek K
Dev Biol (Basel); 2006; 123():29-34; discussion 55-73. PubMed ID: 16566434
[No Abstract] [Full Text] [Related]
50. Insertional oncogenesis in gene therapy: how much of a risk?
Sadelain M
Gene Ther; 2004 Apr; 11(7):569-73. PubMed ID: 15029226
[No Abstract] [Full Text] [Related]
51. Genotoxicity of retroviral integration in hematopoietic cells.
Nienhuis AW; Dunbar CE; Sorrentino BP
Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
[TBL] [Abstract][Full Text] [Related]
52. Is it going to be SIN?: a European Society of Gene Therapy commentary. Phasing-out the clinical use of non self-inactivating murine leukemia virus vectors: initiative on hold.
Buchholz CJ; Cichutek K
J Gene Med; 2006 Oct; 8(10):1274-6. PubMed ID: 17001625
[TBL] [Abstract][Full Text] [Related]
53. [Gene therapy in the treatment of colorectal cancer liver metastases].
Habib N; Jensen S
Bull Acad Natl Med; 2003; 187(5):893-7. PubMed ID: 14979054
[TBL] [Abstract][Full Text] [Related]
54. Gene therapy: shining hopes dented - but not dashed.
Check E
Nature; 2002 Dec 19-26; 420(6917):735. PubMed ID: 12490910
[No Abstract] [Full Text] [Related]
55. Genetic modification of hematopoietic cells using retroviral and lentiviral vectors: safety considerations for vector design and delivery into target cells.
Dropulic B
Curr Hematol Rep; 2005 Jul; 4(4):300-4. PubMed ID: 16009045
[TBL] [Abstract][Full Text] [Related]
56. Gene therapy deserves a fresh chance.
Nature; 2009 Oct; 461(7268):1173. PubMed ID: 19865117
[No Abstract] [Full Text] [Related]
57. Temporary halt on gene therapy trials.
FDA Consum; 2003; 37(2):6. PubMed ID: 12715756
[No Abstract] [Full Text] [Related]
58. Clinical gene-marking of mesenchymal cells.
Horwitz EM; Kasow KA; Hofmann TJ
Cytotherapy; 2003; 5(3):194-6. PubMed ID: 12850786
[No Abstract] [Full Text] [Related]
59. [Current status and future prospective of gene therapy].
Kaneda Y
Nihon Rinsho; 2005 Dec; 63 Suppl 12():469-74. PubMed ID: 16416836
[No Abstract] [Full Text] [Related]
60. Safeguards for gene therapy trials.
FDA Consum; 2003; 37(3):5. PubMed ID: 12793378
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
